1808 – IncobotulinumtoxinA (XEOMIN) injection codes for cerebral palsy spasticity of the lower and/or upper limbs

Change to an existing Medicare Benefits Schedule item.

IncobotulinumtoxinA (Xeomin) is a purified formulation of botulinum neurotoxin that can be used to treat spasticity in individuals 2 years and older with cerebral palsy. The service being requested in this application is the administration of the incobotulinumtoxinA injection to reduce muscle spasms, facilitating mobility and dexterity, improving patient ease of care as well as hygiene/selfcare, facilitating brace use, improving posture, minimizing contractures and deformity as well as reducing pain.

Type: Therapeutic

Cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination. Up to 90% of individuals with cerebral palsy experience spasticity in one or more muscle groups, where muscles spasm or tighten and result in a limited range of passive and active motion. Spasticity can affect the upper and lower limbs reducing function and mobility and ultimately result in contractures which render the limb functionless and may require surgery.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypass PASC
• Pre-MSAC consultation deadline: 13 June 2025 11:59pm AEDT

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Not applicable
• ESC meeting: Not applicable
• MSAC meeting: 31 July to 1 August 2025

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.